Pharmaceuticals, Biotechnology and Life Sciences
Zymerowks’ data for HER2-targeted biospecific antibody ZW25, which will be presented at ESMO, support the Initiation of a Registration-Enabling Phase 2 Trial of the ZW25 in second-line HER2-expressing biliary tract cancers.
AVID200 is a first-in-class, rationally designed inhibitor of TGF-beta 1 & 3, the main oncogenic TGF-beta isoforms AVID200 demonstrated peripheral…
MENLO PARK, Calif.–(BUSINESS WIRE)–GRAIL, Inc., a healthcare company focused on the early detection of cancer, today announced that new data…
Bristol Myers Squib’s adjuvant treatment with Opdivo (nivolumab) further showed extended recurrence-free survival at three years in resected high-risk melanoma patients, being the longest follow-up of any PD-1 inhibitor in the adjuvant melanoma setting.
Merck’s biopharmaceutical branch, EMD Serono, and Pfizer will present clinical activity of treatment with Bavencio across multiple tumor types and patient populations at the European Society for Medical Oncology (ESMO) Congress 2019 in Barcelona, Spain.
Synairgen is confident to get a positive outcome in Part 2 study of Phase 2 trial of its antiviral therapy for Chronic Obstructive Pulmonary Disorder (COPD) patients, in which inhaled IFN-beta is being assessed when patients do have a confirmed respiratory virus infection, after the first part showed positive results.
Sygnature Discovery has developed an AR molecular visualisation prototype, meaning that scientists could soon be rotating virtual molecules in the world around them.
Ipsen’s presentations demonstrate promising advances for the treatment of advanced hepatocellular carcinoma, metastatic pancreatic cancer and neuroendocrine tumors.
Takeda announced further results from the Varsity study, which demonstrated the superiority of the gut-selective biologic vedolizumab (Entyvio) to the anti-tumor necrosis factor-alpha (anti-TNFα) biologic adalimumab (Humira) in achieving the primary endpoint of clinical remission at week 52 in patients with moderately to severely active ulcerative colitis
GW Pharmaceuticals paved a way to launch Epidyolex in Europe, for use as adjunctive therapy of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients 2 years of age and older.